Given the high proportion of MPNST tumors with aberrations in the MAPK pathway, treatment with MEK inhibitors may represent an effective therapy for many patients with the appropriate genotype and merits further prospective evaluation through clinical trials. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.